MaxCyte (NASDAQ:MXCT) Announces Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• MaxCyte reported a quarterly loss of $0.05 per share, beating the consensus estimate of a $0.08 loss; revenue of $8.16 million also topped analysts’ $7.39 million forecast.
• The company agreed to acquire Akron Bio for $151.8 million in cash, stock and deferred payments. MaxCyte expects the deal to broaden its cell-therapy manufacturing business and contribute about $28 million in 2026 revenue.
• Management raised MaxCyte’s 2026 standalone revenue outlook to at least $34.5 million, citing stronger core business performance and SPL milestones and royalties.

MaxCyte (NASDAQ:MXCT - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03, Zacks reports. The business had revenue of $8.16 million for the quarter, compared to analysts' expectations of $7.39 million. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%.

Here are the key takeaways from MaxCyte's conference call:

• Positive Sentiment: MaxCyte agreed to acquire Akron Bio for $151.8 million in cash, stock, and deferred payments. Akron is expected to contribute $28 million in 2026 revenue and $7 million–$8 million in EBITDA; management projects combined 2027 cash burn below $10 million, while the deal will be funded largely with cash and new borrowings.
• Positive Sentiment: Third-quarter revenue rose 49% year over year to $10.2 million, including 27% growth in core revenue. MaxCyte raised its 2026 standalone revenue outlook to at least $34.5 million, citing stronger core performance and SPL milestones and royalties; some instrument purchases arrived earlier than expected.
• Positive Sentiment: Akron would broaden MaxCyte’s exposure across cell therapy manufacturing and more than double its addressable program base, with limited current customer overlap offering cross-selling potential. Management expects the combined company to have more than $60 million in 2026 revenue and identified $3 million–$4 million in potential cost efficiencies.
• Positive Sentiment: MaxCyte reported $2 million in SPL revenue, including $1 million of Casgevy royalties, and said royalty revenue is beginning to become a more meaningful contributor. Vertex reported Casgevy sales of about $99 million in Q3, up roughly 30% sequentially, while MaxCyte said it supports multiple pivotal trials and could have up to three approved products within 24 months.

MaxCyte Price Performance

Shares of NASDAQ MXCT traded down $0.09 during midday trading on Tuesday, reaching $1.21. The company's stock had a trading volume of 2,164,543 shares, compared to its average volume of 1,058,393. The stock has a market capitalization of $124.47 million, a P/E ratio of -3.66 and a beta of 1.49. The firm has a 50 day moving average price of $1.26 and a 200-day moving average price of $1.07. MaxCyte has a 12-month low of $0.64 and a 12-month high of $1.80.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MXCT shares. Weiss Ratings lowered shares of MaxCyte from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, November 4th. BTIG Research reissued a "neutral" rating on shares of MaxCyte in a research report on Monday, August 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $5.00.

About MaxCyte

MaxCyte, Inc NASDAQ: MXCT is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

The company's primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.